Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion (BRAVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03108352
Recruitment Status : Recruiting
First Posted : April 11, 2017
Last Update Posted : September 21, 2018
Sponsor:
Information provided by (Responsible Party):
Chengdu Kanghong Biotech Co., Ltd.

Brief Summary:
The purpose of this study is to verify the efficacy and safety of intravitreal injection of conbercept in patients with macular edema (ME) caused by branch retinal vein occlusion (BRVO).

Condition or disease Intervention/treatment Phase
Branch Retinal Vein Occlusion Macular Edema Drug: Conbercept ophthalmic injection Other: sham injection Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 252 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multi-center, Randomized, Double-masked, Placebo-controlled Phase III Clinical Study of Conbercept Ophthalmic Injection for Patients With BRVO.
Study Start Date : May 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arm Intervention/treatment
Experimental: Conbercept ophthalmic injection
Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)
Drug: Conbercept ophthalmic injection
Sham Comparator: sham/Conbercept ophthalmic injection
Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)
Drug: Conbercept ophthalmic injection
Other: sham injection



Primary Outcome Measures :
  1. Best Corrected Visual Acuity [ Time Frame: month 6 ]
    Compare mean changes in Best Corrected Visual Acuity (BCVA) from baseline between the Conbercept ophthalmic injection treatment group (treatment group) and the control group at month 6.


Secondary Outcome Measures :
  1. Best Corrected Visual Acuity (BCVA) [ Time Frame: month 3 and month 12 ]
    1>o evaluate mean changes in BCVA from baseline of the treatment group and the control group at month 3 and 12.

  2. Central Retinal Thickness [ Time Frame: month 3, month 6 and month 12 ]
    To evaluate mean changes in Central Retinal Thickness (CRT) from baseline of the treatment group and the control group at month 3, 6 and 12.

  3. resue treament [ Time Frame: month 6 and month 12 ]
    To evaluate the number of subjects who received laser rescue treatment of the treatment group and the control group at month 6 and 12.

  4. Number of participants with treatment-related the systemic and ocular safely as assessed [ Time Frame: up to 12.5 months ]
    To evaluate the systemic and ocular safety of the treatment group and the control group.

  5. distribution of BCVA changes [ Time Frame: month 3, month 6 and month 12 ]
    To evaluate the distribution of BCVA changes from baseline of the treatment group and the control group at month 3, 6 and 12.

  6. mean changes in BCVA [ Time Frame: month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12 ]
    To evaluate mean changes in BCVA from baseline of the treatment group and the control group at every visit.

  7. Change in image [ Time Frame: month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12 ]
    To evaluate the average changes in imaging findings (e.g., CRT and total macular volume) relative to the baseline for treatment group and control group at each follow-up visit.


Other Outcome Measures:
  1. Immunogenic positive response in the treatment group [ Time Frame: baseline,month 6, month 12 ]
    Number of participants with Treatment-Ralated positive response to anti-drug antibody(ADA)or neutralizing antibody(Nab) in the treatment group at baseline,6 and 12months.

  2. Immunogenic positive response in the control group [ Time Frame: baseline,month 6, month 12 ]
    Number of participants with Treatment-Ralated positive response to anti-drug antibody(ADA)or neutralizing antibody(Nab) in thecontrol group at baseline,6 and 12months.

  3. safety analysis of immunogenic positive response [ Time Frame: month 12 ]
    To analyze the safely of subjects with positive response to ADA or Nab at 12 months after treatment and number of participants with positive respone who develop anticipants immuogenic adverse events.

  4. safety analysis of immunogenic negative response [ Time Frame: month 12 ]
    To analyze the safely of subjects with negative response to ADA or Nab at 12 months after treatment and number of participants with negative response who develop anticipants immuogenic adverse events.

  5. Best Corrected Visual Acuity (BCVA) [ Time Frame: month 12 ]
    To analyze the BCVA for subjects with positive response to ADA or Nab at 12 months after treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients have signed informed consent form and agreed to be followed up as per the trial protocol;
  • Aged ≥ 18 years, male or female;
  • Study eyes must meet all of following requirements:

    • Suffering from macular edema secondary to BRVO that involves the fovea and BRVO has been first diagnosed within previous 12 months;
    • Best corrected visual acuity (BCVA) ≥24 and ≤73 letters (Snellen equivalent is 20/320 - 20/40);
    • Central retinal thickness (CRT) on OCT is ≥300 μm;
  • Without opacities in the refractive media and pupillary miosis that affects fundus examination.

Note: The eye of interest is determined by the researcher from a medical point of view if both eyes of the patient meet the inclusion criteria. In principle, the eye with poor eyesight or thicker central retina should be selected as the eye of interest.

Exclusion Criteria:

Any subject who has any of the following ocular condition:

  1. Eye of interest

    • Has active retina and/or iris neovascularization;
    • Has macular epiretinal membranes or vitreous tractions which are considered to influence the central visual acuity by the researcher;
    • Has other diseases which are considered to influence the macular functional recovery by the researcher, e.g., foveal atrophy, subfoveal hemorrhage, macular hard exudates or dense submacular hard exudates;
    • Has a history of any type of retinal detachment;
    • Has non-RVO ocular diseases which are considered to possibly cause macular edema, declined visual acuity or retinal neovascularization during the study period by the researcher, e.g., wet AMD, diabetic retinopathy, uveitis/other intraocular inflammatory diseases, neovascular glaucoma and cystoid macular edema;
    • Is considered to require cataract surgery in the next 12 months by the researcher;
    • Has received intravitreal injection of corticosteroids within three months before screening, subconjunctival injection of corticosteroids within six months, or local treatment with ocular corticosteroids within one month;
    • Has received the following ophthalmic operations: scleral buckling, verteporfin-photodynamic therapy (PDT), vitrectomy, radial optic neurotomy/optic nerve sheathotomy, glaucoma filtration, parafoveal laser photocoagulation, pan-retinal photocoagulation, and macular translocation;
    • Has received YAG laser treatment or any other ophthalmic treatments (including cataract surgery, macular grid laser photocoagulation, local retinal photocoagulation, and keratoplasty) within three months before screening;
    • Has a BCVA increment by more than 10 alphabets during the screening period (BCVA tested within 24 hours before medication at Day 0 versus BCVA at the time of screening);
    • Has aphakic eye (excluding pseudophakic) or or posterior lens capsule (except YAG laser posterior capsulotomy after intraocular lens implantation);
  2. Either eye:

    • Has active periocular or ocular inflammation (e.g., blepharitis, infective conjunctivitis, keratitis, scleritis, uveitis, and endophthalmitis);
    • Has previous or existing uncontrollable glaucoma (defined as IOP remaining at ≥ 30 mmHg after anti-glaucoma treatment), or has a cup-to-disc ratio of the eye of interest of above 0.8 due to severe glaucoma;
    • Has received intravitreal injection of any anti-VEGF agents (e.g.,ranibizumab, bevacizumab, and conbercept) within three months before screening;

Patient with any of the following systemic diseases:

  • Has a history of anaphylaxis and allergy to fluorescein sodium, and of allergy to protein products for diagnosis or treatment, and is allergic to no less than two drugs and/or non-drug factors, or suffers from allergic diseases now;
  • Has a history of stroke, has a history of myocardial and/or cerebral infarction(s) and of transient cerebral ischemia within 6 months before screening, and has active and disseminated intravascular coagulation and distinct bleeding tendency;
  • Has confirmed systemic immune disease (e.g., ankylosing spondylitis, systemic lupus erythematosus, and Behcet's disease, rheumatoid arthritis, and scleroderma);
  • Has any uncontrollable clinical problem (e.g., AIDS, active hepatitis, severe mental, neurological, cardiovascular and respiratory diseases, and malignancies);
  • Hyperpietics with poor blood pressure control (defined as SBP remaining at ≥ 160 mmHg or DBP remaining ≥ 100 mmHg after antihypertensives therapy);
  • Has a surgical history within one month before screening, and/or has unhealed wounds, ulcers and fractures at present;
  • Has systemically used corticosteroids (orally, intramuscularly, intravenously) within 6 months before screening;
  • Has received systemic treatment with anti-VEGF agent(s) (e.g., bevacizumab) within 6 months before screening; Patients with any of the following abnormal laboratory tests
  • Those who have hepatic, renal and immunologic dysfunction (this trial specifies that ALT and AST are twice as high as the ULN of this central laboratory, and that Crea and BUN are 1.5-fold as high as the ULN of this central laboratory);
  • Those who have coagulation abnormalities (PT is 3 seconds greater than or equal to the ULN, and APTT is 10 seconds greater than or equal to the ULN); Patients of childbearing age with any of the following condition
  • Those who do not take effective contraceptive measures at childbearing age; Note: The following conditions are not included in the exclusion range.

    1. Amenorrhea for 12 months under the natural condition, or amenorrhea for 6 months under the natural condition and the serum FSH level of < 40 mIU/ml;
    2. Six weeks after bilateral ovariectomy with/without hysterectomy;
    3. Use of the following one or more acceptable contraceptions:

      • Sterilization (for males, with bilateral vasoligation and vasectomy)
      • Hormonal contraception (implantable, patchable, oral)
      • Intrauterine device and dural barrier method
    4. Ability to take reliable contraceptive measures over the study period and hold on to 30 days after study drug withdrawal (unacceptable contraceptive methods include: periodic continence - according to the calendar and ovulatory phase, body thermometry, post-ovulatory method, and coitus interruptus);
  • Pregnant women and breastfeeding mothers (in this trial pregnancy is defined as positive U-HCG); Others
  • Patient has participated in any drug (not including vitamins and minerals) clinical trial three months before screening (if the study drug has a long half-life, i.e., its five half-lives exceed three months, then it is deemed as five half-lives); Any condition in which the researcher deems necessary to be excluded in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03108352


Contacts
Layout table for location contacts
Contact: wenbin weni 86-010-58269152 tr_weiwenbin@163.com

Locations
Layout table for location information
China
Beijing Friendship Hospital, Capital Medical University Recruiting
Beijing, China
Contact: Yanling WANG         
Peking University People's Hospital Recruiting
Beijing, China
Contact: Xiaoxin LI         
Beijing Tongren Hospital, Capital Medical University Recruiting
Peking, China
Contact: wenbin WEI         
Zhongshan Hospital Recruiting
Shanghai, China
Contact: Fei YUAN         
Tianjin Medical University Eye Hospital Recruiting
Tianjing, China
Contact: Xiaorong LI         
The Eys Hosptial of Wenzhou Medical University Recruiting
Wenzhou, China
Contact: Xiaoling LIU         
The Frist Affiliated Hospital of Xi'an Jiaotong University Recruiting
Xi'an, China
Contact: Li QIN         
Sponsors and Collaborators
Chengdu Kanghong Biotech Co., Ltd.

Layout table for additonal information
Responsible Party: Chengdu Kanghong Biotech Co., Ltd.
ClinicalTrials.gov Identifier: NCT03108352     History of Changes
Other Study ID Numbers: KH902-BRVO-CRP-1.0
First Posted: April 11, 2017    Key Record Dates
Last Update Posted: September 21, 2018
Last Verified: September 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Edema
Macular Edema
Retinal Vein Occlusion
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases